We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Tenofovir disoproxil fumarate/emtricitabine is associated with a higher risk of hypocalcemia compared to abacavir/lamivudine - results from a German cohort study.
- Authors
Noe, S; Heldwein, S; Jaeger, H; Page, M; Wolf, E
- Abstract
Hyperparathyroidism has been described in people living with HIV undergoing tenofovir disoproxil fumarate (TDF)-containing antiretroviral therapy (ART), but differences in calcium levels have never been investigated in detail. We aimed to compare the prevalence of hypocalcemia between patients with and without TDF-containing ART. The patients and methods were a retrospective cohort study in HIV-infected adult patients receiving dolutegravir and either abacavir (ABC)/lamivudine (3TC) or TDF/emtricitabine in a single center in Munich, Germany. Of 172 patients, 126 (73.3%) were male and the median age was 48.5 years (interquartile range 42-54). Average calcium levels were 2.24 (2.21-2.29) mmol/l and 2.21 (2.16-2.26) mmol/l (P < 0.001) with a prevalence of at least one episode of total calcium <2.12 mmol/l of 16.2 and 34.4% in the groups treated with ABC/3TC and TDF/emtricitabine, respectively (P = 0.006). TDF use was independently associated with the occurrence of albumin-corrected calcium levels of <2.12 mmol/l (odds ratio: 6.7 [1.3-35.6]; P = 0.025). Hypocalcemia seems to occur more often in TDF-treated patients. Further research into hypocalcemia with TDF and potential cardiovascular effects may be of benefit based on these findings.
- Subjects
GERMANY; MUNICH (Germany); HYPOCALCEMIA; COHORT analysis; AMERICAN Broadcasting Co.; BISOPROLOL; TENOFOVIR; ODDS ratio; CALCIUM; COMBINATION drug therapy; COMPARATIVE studies; HETEROCYCLIC compounds; HIV infections; LONGITUDINAL method; RESEARCH methodology; MEDICAL cooperation; RESEARCH; EVALUATION research; HIGHLY active antiretroviral therapy; TREATMENT effectiveness; DISEASE prevalence; RETROSPECTIVE studies; LAMIVUDINE; ANTI-HIV agents; HIV integrase inhibitors; DEOXYRIBONUCLEOSIDES
- Publication
International Journal of STD & AIDS, 2019, Vol 30, Issue 5, p447
- ISSN
0956-4624
- Publication type
journal article
- DOI
10.1177/0956462418815022